Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

The immunogenicity of peptides is believed to be determined by their high-affinity binding to MHC I. Here authors show that low-affinity MHC I-peptide interactions are also able to trigger robust T cell response and anti-tumour immunity in vivo.

Guardado en:

Detalles Bibliográficos
Autores principales:	Hakimeh Ebrahimi-Nik, Marmar Moussa, Ryan P. Englander, Summit Singhaviranon, Justine Michaux, HuiSong Pak, Hiroko Miyadera, William L. Corwin, Grant L. J. Keller, Adam T. Hagymasi, Tatiana V. Shcheglova, George Coukos, Brian M. Baker, Ion I. Mandoiu, Michal Bassani-Sternberg, Pramod K. Srivastava
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/1e4f015d0d0f4721934a300013d3a61f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e4f015d0d0f4721934a300013d3a61f
record_format	dspace
spelling	oai:doaj.org-article:1e4f015d0d0f4721934a300013d3a61f2021-11-08T11:10:40ZReversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope10.1038/s41467-021-26646-52041-1723https://doaj.org/article/1e4f015d0d0f4721934a300013d3a61f2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26646-5https://doaj.org/toc/2041-1723The immunogenicity of peptides is believed to be determined by their high-affinity binding to MHC I. Here authors show that low-affinity MHC I-peptide interactions are also able to trigger robust T cell response and anti-tumour immunity in vivo.Hakimeh Ebrahimi-NikMarmar MoussaRyan P. EnglanderSummit SinghaviranonJustine MichauxHuiSong PakHiroko MiyaderaWilliam L. CorwinGrant L. J. KellerAdam T. HagymasiTatiana V. ShcheglovaGeorge CoukosBrian M. BakerIon I. MandoiuMichal Bassani-SternbergPramod K. SrivastavaNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Hakimeh Ebrahimi-Nik Marmar Moussa Ryan P. Englander Summit Singhaviranon Justine Michaux HuiSong Pak Hiroko Miyadera William L. Corwin Grant L. J. Keller Adam T. Hagymasi Tatiana V. Shcheglova George Coukos Brian M. Baker Ion I. Mandoiu Michal Bassani-Sternberg Pramod K. Srivastava Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
description	The immunogenicity of peptides is believed to be determined by their high-affinity binding to MHC I. Here authors show that low-affinity MHC I-peptide interactions are also able to trigger robust T cell response and anti-tumour immunity in vivo.
format	article
author	Hakimeh Ebrahimi-Nik Marmar Moussa Ryan P. Englander Summit Singhaviranon Justine Michaux HuiSong Pak Hiroko Miyadera William L. Corwin Grant L. J. Keller Adam T. Hagymasi Tatiana V. Shcheglova George Coukos Brian M. Baker Ion I. Mandoiu Michal Bassani-Sternberg Pramod K. Srivastava
author_facet	Hakimeh Ebrahimi-Nik Marmar Moussa Ryan P. Englander Summit Singhaviranon Justine Michaux HuiSong Pak Hiroko Miyadera William L. Corwin Grant L. J. Keller Adam T. Hagymasi Tatiana V. Shcheglova George Coukos Brian M. Baker Ion I. Mandoiu Michal Bassani-Sternberg Pramod K. Srivastava
author_sort	Hakimeh Ebrahimi-Nik
title	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
title_short	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
title_full	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
title_fullStr	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
title_full_unstemmed	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope
title_sort	reversion analysis reveals the in vivo immunogenicity of a poorly mhc i-binding cancer neoepitope
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1e4f015d0d0f4721934a300013d3a61f
work_keys_str_mv	AT hakimehebrahiminik reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT marmarmoussa reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT ryanpenglander reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT summitsinghaviranon reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT justinemichaux reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT huisongpak reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT hirokomiyadera reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT williamlcorwin reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT grantljkeller reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT adamthagymasi reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT tatianavshcheglova reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT georgecoukos reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT brianmbaker reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT ionimandoiu reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT michalbassanisternberg reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope AT pramodksrivastava reversionanalysisrevealstheinvivoimmunogenicityofapoorlymhcibindingcancerneoepitope
_version_	1718442312259862528

Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope

Ejemplares similares